Top News
Adding Nivolumab to Standard Care Does Not Improve Survival in Glioblastoma
Fyarro Approved for Malignant Perivascular Epithelioid Cell Tumor
Structured Exercise Aids Recovery From Breast Cancer Surgery
Blacks, Hispanics Still Underrepresented in Cancer Clinical Trials
ICU Bed Occupancy During COVID-19 Linked to Increase in Excess Deaths
Neuro-Oncology Patient Satisfaction Maintained During COVID-19 Pandemic
Treatment-Related Regret Common in Prostate Cancer
Long-Term Safety Data Support Benefit-Risk Profile of NBTXR3 Plus Radiotherapy in Locally Advanced Soft Tissue Sarcoma
CEBPA-bZip Mutations Associated With Favorable Prognosis in Acute Myeloid Leukemia
Fewer Deaths Reported With Enrollment in COVID-19 Remote Monitoring
Patients Hospitalized With COVID-19 Less Likely to Be Vaccinated
EDITORIAL ADVISORY BOARD
E. David Crawford, MD
Jeffrey M. Farma, MD
Featured
-
Parents Report Challenging Relationships With Pediatric Oncology Clinicians
Asian parents were more likely to report challenging relationships. -
Men and Women Differ in Their Refusal of Breast Cancer Treatments
The odds of refusing hormone therapy, surgery, and radiation differed by sex. -
Digital Symptom Monitoring Can Improve Outcomes of Cancer Care
Patients experienced clinically meaningful benefits at various time points. -
Can Quality of Life Assessments Predict PFS, OS Across Cancer Types?
Recent studies showed associations between quality of life scores and survival in lung and prostate cancer as well as renal cell carcinoma. -
Treatment Sequence Impacts Survival in BRAF-Mutant Metastatic Melanoma
The 2-year overall survival rate was higher for patients who started treatment with nivolumab-ipilimumab than for those who started with dabrafenib-trametinib. -
Adding Ibrutinib to R-CHOP Doubles EFS in 2 Subgroups of Diffuse Large B-Cell Lymphoma
Younger patients with the MCD and N1 subtypes of DLBCL had 3-year event-free survival rates of 100% when they received ibrutinib plus R-CHOP. -
Racial/Ethnic Disparities in MRI Use May Affect Prostate Cancer Diagnosis
Asian, Black, and Hispanic patients were all less likely than White patients to undergo a prostate MRI. -
Immune Checkpoint Inhibitors May Not Benefit Trial-Ineligible Cancer Patients
The restricted mean survival times were similar at 12 months and 36 months. -
Genetic Differences May Partly Explain Racial/Ethnic Disparities in Early-Onset Colorectal Cancer
Data from the GENIE registry revealed distinct genomic patterns in patients of different races/ethnicities.
More Features
Long-Term Benefit With Abemaciclib in High-Risk Early Breast Cancer
The benefit was maintained beyond the 2-year treatment period.
Docs Disagree With Update to NCCN Guidelines for Prostate Cancer
An update to active surveillance recommendations has some physicians concerned.
PTSD in Cancer Patients: What Providers Need to Know
Experts outline risk factors for PTSD and explain how PTSD can affect cancer outcomes.
Equal Access to Care May Eliminate Racial Disparities in Lung Cancer Outcomes
One study suggested that modifiable factors could improve racial disparities in the stage at which lung cancer is diagnosed.
Genomic Sequencing in Pediatric Cancer: For Every Patient at Every Relapse
More than one-third of tumors sequenced carried a high mutation burden.
- Loading...
Loading...
Loading... 
Loading...